LGVN - Longeveron gains after announcing mid-stage trial for Lomecel-B in aging

After two consecutive sessions of double-digit losses, Longeveron (LGVN +9.1%) turned positive after announcing an agreement with two Japanese institutions to conduct a Phase 2 trial for Lomecel-B for older, frail subjects in the country. Per the sponsored clinical research agreement signed by the company with National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital in Japan, Lomecel-B will be assessed in a randomized, double-blind, placebo-controlled study. The trial is expected to enroll 45 subjects across three cohorts. A cell-based therapy product derived from the bone marrow of young and healthy adult donors, Lomecel-B has undergone Phase 1 & 2 clinical studies in the U.S. for aging frailty. It was granted the rare pediatric disease designation by the FDA for Hypoplastic Left Heart Syndrome (HLHS).

For further details see:

Longeveron gains after announcing mid-stage trial for Lomecel-B in aging